Wednesday, June 1, 2016

BRIEF-Chemocentryx receives priority medicines designation from EMA for CCX168

* Chemocentryx Inc says received priority medicines

designation from EMA for CCX168 for treatment of anca-associated

vasculitis

Source text for Eikon:

Further company coverage:

(Bengaluru Newsroom: +1-646-223-8780)

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)